Thrombotic thrombocytopenic purpura  by Tellez-Hinojosa, C. et al.
MR
T
C
U
M
R
A
I
E
f
t
t
d
e
t
p
s
v
L
N
(
h
1
Cedicina Universitaria. 2015;17(69):234--239
www.elsevier.es/rmuanl
EVIEW ARTICLE
hrombotic  thrombocytopenic  purpura
. Tellez-Hinojosa, A. Vazquez-Mellado, D. Gómez-Almaguer ∗
niversidad  Autónoma  de  Nuevo  León,  Hematology  Service  at  ‘‘Dr.  José  Eleuterio  González’’  University  Hospital,
onterrey, México
eceived  22  September  2015;  accepted  30  October  2015
vailable  online  23  April  2016
KEYWORDS
Thrombotic
thrombocytopenic
purpura;
Plasmapheresis;
Rituximab;
Diagnosis;
Treatment;
Abstract  Thrombotic  thrombocytopenic  purpura  (TTP)  is  a  disease  with  a  high  rate  of  mortality
if a  proper  treatment  is  not  instated.  Plasmapheresis  with  plasmatic  exchange  is  the  treatment
of choice.  Diagnosis  is  performed  demonstrating  microangiopathic  hemolytic  anemia,  a  negative
direct Coombs  test  and  thrombocytopenia.  Among  the  clinical  data,  neurological  and  renal
alterations  stand  out.  When  there  is  a  reasonable  suspicion  in  the  diagnosis,  plasmapheresis
must be  initiated  immediately.  There  are  different  diseases  that  may  be  similar  to  the  TTP
signs and  symptoms,  especially  in  pregnant  women.  TTP  has  a  high  risk  of  relapse  and  may
leave sequelae.Classiﬁcation ©  2016  Universidad  Auto´noma  de  Nuevo  Leo´n.  Published  by  Masson  Doyma  Me´xico  S.A.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
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li  Moschowitz  was  the  ﬁrst  to  describe  TTP,  when  per-
orming  the  autopsy  of  a  16-year-old  girl  whom  he  had
reated.  During  this  autopsy,  Moschowitz  found  hyaline
hrombi  occluding  the  arterioles  and  capillaries,  he  later
escribed  them  as  ‘‘aggregated  platelets’’.1 The  pres-
nce  of  hemolytic  anemia,  negative  Coombs,  schistocytes,
hrombocytopenia,  and  high  lactate  dehydrogenase  (LDH)  in
atients  with  neurological  and/or  renal  alterations9 strongly
uggests  a  TTP  diagnosis.
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C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4TTP  has  a  mortality  rate  of  90%  without  treatment.2 The
rst  attempts  to  reduce  mortality  involved  large  doses  of
teroids.3 The  following  attempt  included  the  use  of  fresh
lood.4 Undoubtedly,  the  turning  point  in  TTP  treatment  was
he  use  of  plasma,  which  ﬁrst  took  place  in  1977.5 One  of  the
reatest  progresses  concerning  the  comprehension  of  the
hysiopathology  of  this  disease  was  to  identify  the  unusu-
lly  long  von  Willebrand  factors  multimers,6 and  later,  to
dentify  the  deﬁciency  of  the  protease  in  charge  of  splitting
his  multimers  in  congenital  TTP,7 and  lastly,  to  identify  that
rotease  as  the  thirteenth  member  of  the  ADAMTS  family
a  disintegrin  and  metalloproteinase  with  thrombospondin-1
epeats).8hrombotic  thrombocytopenic  purpura  (TTP)  is  a  pathology
hich  puts  the  patient’s  life  in  danger,  with  a  mortality  rate
asson Doyma Me´xico S.A. This is an open access article under the
.0/).
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Table  1  Classiﬁcation  of  TTP.
Type  Trigger
Congenital
(Upshaw--Shulman
syndrome)
Mutation  in  the  gene
responsible  for  synthesizing
ADAMTS13.
Acquired  or  idiopathic  Autoantibodies  against
ADAMTS13.
Related  to  pregnancy
Drug-related  Clopidogrel,  ticlopidine.
HIV-related
Related  to  chemotherapy Cyclosporin  A,  mitomycin  C.
Related  to Associated  with  the  use  of
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lThrombotic  thrombocytopenic  purpura  
of  over  90%  when  a  plasmapheresis  with  plasmatic  exchange
treatment  is  not  instated.  It  may  affect  multiple  systems  and
organs,  the  nervous  system  being  the  one  that  is  usually  the
most  affected.  Secondly,  it  affects  the  renal  function  due
to  the  microthrombus  occluding  the  microvasculature.  It  is
clinically  characterized  by  two  main  laboratory  alterations:
thrombocytopenia  and  microangiopathic  hemolytic  anemia.
Direct  Coombs  test  results  are  negative  and  LDH  is  invariably
increased.
Etiology
TTP  is  classiﬁed  according  to  its  etiology  (Chart  1),  although
TTP  can  be  congenital,  as  a  result  of  a  mutation  of  the
gene  responsible  for  desynthesizing  ADAMTS13.10 The  most
common  form  of  TTP  is  idiopathic  or  autoimmune,  where
antibodies  directed  against  ADAMTS13  are  created.11
Pregnancy  is  among  the  causes  of  TTP,  even  though  diag-
nosis  in  these  cases  is  complicated  because  the  clinical  and
laboratory  ﬁndings  are  very  similar  to  pregnancy-related
syndromes  like  preeclampsia  and  the  HELLP  syndrome.  In
the  case  of  TTP,  the  signs  and  symptoms  are  more  severe
and  the  quantiﬁcation  of  ADAMS-13  is  useful,  since  in  other
pathologies  it  is  usually  normal.12 Some  medications  have
been  linked  to  the  appearance  of  TTP,  quinine  being  the
main  responsible.13 Clopidogrel,  ticlopidine,  cyclosporine  A
and  mitomycin  C,  among  others,  have  also  been  linked  as
TTP  triggers.14
Chemotherapy,  hematopoietic  stem  cell  transplants,  HIV,
and  lupus  are  factors  frequently  related  to  TTP.  They  are,
however,  poorly  understood.  Hematopoietic  stem  cell  post-
transplant  TTP  is  linked  to  the  use  of  cyclosporine  A  and  is
usually  a  severe  clinical  picture,  and  it  is  difﬁcult  to  make
the  patient  enter  remission.15,16
Epidemiology
Young  women  are  more  prone  to  this  disease.  In  2005,
there  was  a  study  published  reporting  the  incidence  of  TTP
and  hemolytic  uremic  syndrome  (HUS),  using  records  which
included  all  patients  sequentially  for  whom  plasmapheresis
treatment  is  requested  by  the  Oklahoma  Blood  Institute  due
to  clinical  suspicion  of  TTP  or  HUS,  based  on  the  presence  of
microangiopathic  hemolytic  anemia  and  thrombocytopenia
without  an  apparent  etiology.
The  incidence  rate  for  all  patients  with  clinical  suspicion
of  TTP-HUS  in  the  Oklahoma  records  was  11.29  per  mil-
lion  inhabitants.  The  incidence  rate  for  idiopathic  TTP-HUS
patients  was  4.6  per  million  inhabitants,  and  the  incidence
rate  for  patients  with  severe  ADAMTS13  deﬁciency  was  1.74
per  million  inhabitants.
The  incidence  rate  of  TTP  associated  with  severe
ADAMTS13  deﬁciency  is  over  9  times  higher  in  black  people
than  other  races.  The  incidence  rate  of  TTP-HUS  comparing
women  with  men  was  >1.17Physiopathology
The  main  histological  ﬁnding  in  TTP  is  hyaline  thrombi,
formed  by  platelet  aggregation.  These  thrombi  are
n
b
t
nhematopoietic  stem
cell  transplant
cyclosporin  A
esponsible  for  capillary  occlusion,  with  the  subsequent
schemia  in  different  organs.1,18
The  von  Willebrand  Factor  (vWF)  plays  a  key  role  in
latelet  aggregation.  VWF  produced  exclusively  in  endothe-
ial  cells  and  platelets,  is  stored  as  Wiebel-Palade  granule  in
ndothelial  cells  and  as  -granule  in  platelets.  Within  these
ranules  it  is  stored  in  an  ultra-large  shape  (ULvWF).7 After
eing  secreted,  ULvWF  attaches  to  the  endothelial  surface.
he  longer  the  vWF  is,  the  greater  the  effect  on  platelet
ggregation,  because  it  is  more  related  to  the  platelet’s  Ib
eceptor.  The  role  of  ADAMTS13  is  to  split  the  ULvWF  into
mallest  molecules.9,19 In  congenital  TTP,  ADAMTS13  activity
ay  be  lower  than  5%,  due  to  mutations  in  the  gene  respon-
ible  for  ADAMTS13  production.10 Regarding  idiopathic  TTP,
ndings  show  that  it  is  an  autoimmune  process,  mediated
y  IgG-class  antibodies.11 Even  though  ADAMTS13  deﬁciency
s  suggested  as  the  main  culprit,  it  is  important  to  men-
ion  the  fact  that  other  causes  have  been  studied,  such
s  lymphocytes,  macrophageactivation,  high  IL-1,  IL-6,  IL-2
nd  TNF- levels,  and  transforming  growth  factor  (TGF)-,
mong  others.20,21
igns, symptoms and laboratory ﬁndings
lassically,  a  pentad  is  described,  consisting  of  throm-
ocytopenia,  microangiopathic  hemolytic  anemia,  fever,
eurological  symptoms  and  renal  dysfunction.2 It  is  worth
tressing  that  currently  this  pentad  is  rarely  seen,  since
reatment  with  plasmapheresis  is  instated  before  it  occurs.
owadays,  the  only  thing  required  is  thrombocytopenia  and
icroangiopathic  hemolytic  anemia  in  order  to  establish
iagnosis,  and,  as  mentioned  above,  the  presence  of  schis-
ocytes,  a  negative  direct  Coombs  and  a high  LDH  conﬁrm
linical  suspicion  of  TTP  (Tables  1  and  2).
Clinical  ﬁndings  which  pave  the  way  to  thrombocytopenia
uspicion  are  epistaxis,  menorrhagia,  hematuria,  gingivor-
hagia,  etc.  Nevertheless,  signiﬁcant  hemorrhage  data  is  not
ecessarily  found,  as  in  the  case  of  autoimmune  thrombocy-
openic  purpura.  Platelets  are  below  normal  levels,  typically
ess  than  20  ×  109/L.  Lab  work  shows  hemoglobin  below
ormal  levels,  elevated  reticulocytes,  elevated  indirect
ilirubin,  elevated  LDH,  low  haptoglobin,  normal  coagula-
ion  time,  usually  in  early  stages  of  the  disease,  and  a
egative  Coombs  direct  test  can  also  be  used.  In  a  peripheral
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Table  2  Recommended  studies  for  patients  with  a  sus-
pected  TTP  diagnosis.30
Recommended  study  Result  compatible  with  a  TTP
diagnosis
CBC  Anemia,  thrombocytopenia,
and  elevated  reticulocytes
Peripheral  blood  smear  Schistocytes
Clotting  times  Normal
DHL  Very  high
Liver  function  tests  Elevated  indirect  bilirubin
Urea nitrogen,  creatinine. Renal  dysfunction
Direct  Coombs Negative
ADAMTS  13  (inhibitor,
activity,  antibody)
Do  not  wait  for  the  result  to
begin  treatment.
Troponin  T,  EKG.  To  assess  myocardial  damage
HIV serology
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30,33CAT-scan  or  brain  MR  To  assess  neurological  damage
Pregnancy  test  (women)
lood  smear  we  are  able  to  observe  schistocytes  or  creno-
ytes  due  to  their  mechanical  fragmentation  when  going
hrough  occluded  capillaries.22,23
Regarding  nervous  system  symptoms,  in  summary  these
re  the  focal  symptoms:  cephalalgia,  paresis,  aphasia,  cog-
itive  deterioration,  and  transitory  ischemic  accidents.
enal  dysfunction  is  not  as  marked  as  hemolytic  uremic
yndrome,  and  rarely  requires  dialysis,24 though  proteinuria
nd  oliguria,  among  others,  may  appear.  It  is  important  to
ake  cardiac  affection  into  consideration.  This  is  typically
nder  diagnosed,  and  may  occur  in  acute  infarction,  con-
estive  cardiac  failure,  arrhythmias,  cardiogenic  shock,  and
ven  sudden  death.25,26 The  disease’s  natural  course  without
reatment  leads  to  death  for  90%  of  patients  in  a  matter  of
ays.27
ifferential diagnoses
emolytic  uremic  syndrome  (HUS)
t  is  usually  preceded  by  a  period  of  hemorrhagic  enterocoli-
is  caused  by  the  shiga  toxin,  produced  by  diverse  serotypes
f  E.  coli  (i.e.  0157:H7)  or  Shigella  spp.,  particularly  in  chil-
ren.  HUS  is  a  disorder  in  the  activation  of  a  complement,
n  order  to  diagnose  it,  it  is  necessary  to  prove  the  presence
f  the  shiga  toxin  and  for  the  complement  to  be  depleted.
here  are  two  types  of  HUS,  the  typical  type  which  occurs
n  children  and  the  patient  usually  recovers  on  his/her  own,
nd  the  atypical,  which  is  most  common  in  adults.  Some-
imes  there  is  no  diarrhea  or  a  clear  trigger  and  the  patient’s
ourse  with  renal  failure,  which  in  most  cases  evolves  into
enal  failure  that  require  dyalisis.24,28
reeclampsiat  develops  in  the  2nd  or  3rd  trimester,  with  the  onset  of
ypertension  and  proteinuria  after  week  20  of  pregnancy.
ess  than  5%  of  women  with  preeclampsia  will  develop
evere  thrombocytopenia.12
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ELLP  syndrome
emolysis,  Elevated  Liver  enzymes  and  Low  Platelets
HELLP).  A  key  point  in  the  diagnosis  of  this  pathology  is
hat  ADAMTS13  activity  is  normal.  Lab  work  shows  an  ele-
ation  of  LDH,  AST,  and  thrombocytopenia.  A  LDH/AST  ratio
22.12  suggests  that  a  TTP  diagnosis  is  more  probable  than
ELLP  syndrome  in  pregnant  patients  during  their  third
rimester.12,29
iagnostic methods
iagnosis  is  performed  through  clinical  history  and  the  exam-
nation  of  a  peripheral  blood  smear.  The  measurement  of
DAMTS13  levels  and  anti  ADAMTS13  antibodies  is  recom-
ended;  however,  plasmapheresis  and  plasma  exchange
reatment  should  not  be  delayed  while  waiting  for  the
esults  of  these  measurements.  The  requirements  to  begin
lasmapheresis  are  merely  the  presence  of  schistocytes  in
eripheral  blood  (more  than  2  per  ﬁeld),  anemia,  thrombo-
ytopenia  and  elevation  of  LDH.
As  previously  pointed  out,  the  classic  pentad  of  clini-
al  signs  and  symptoms  is  no  longer  considered  current;
owadays  the  presence  of  thrombocytopenia  and  microan-
iopathic  hemolytic  anemia  is  enough  to  create  the  suspicion
f  a  TTP  diagnosis.  The  recommended  laboratory  tests  to
equest  (chart  2)  are  useful  in  order  to  conﬁrm  diagnostic
uspicion  of  TTP,  rule  out  differential  diagnoses  and  to  assess
hite  organ  damage.30
urrent treatment
lasmapheresis  with  plasma  exchange  is  the  treatment  of
hoice.  This  therapy  should  begin  immediately  if  there  is
he  suspicion  of  TTP.
Plasmapheresis  has  two  main  objectives:
 Withdrawal  of  the  ADAMTS13  inhibitor  (IgG),  as  well  as
most  of  the  ULvWF  chains.
 Replacement  of  deﬁcient  or  missing  ADAMTS13.
Plasmapheresis  is  superior  to  plasma  infusion.31 How-
ver,  it  is  possible  to  use  a  high  dose  of  plasma  infusion
20--30  ml/kg/day)  as  an  initial  therapy,  especially  when
here  is  no  access  to  resources  to  begin  plasmapheresis,
nd  even  though  there  is  the  risk  of  a  volume  overload
nd  proteinuria  exacerbation.  Plasma  infusion  is  not  a  sub-
titute  for  plasmapheresis;  it  just  functions  as  a  bridge
herapy.32
The  exact  duration  of  treatment  and  the  necessary
umber  of  sessions  is  highly  variable  between  patients,
epending  on  the  presence  or  the  title  of  the  autoantibody
nd  ADAMTS13  activity.
British  guidelines  establish  plasmapheresis  to  be  started
ith  1.5  times  plasma  volume  for  3  days,  and  reassess  the
atient  daily.  They  recommend  the  use  of  plasma  treated
ith  solvent/detergent  where  with  the  risk  of  infections
nd  adverse  immune  responses  decreases. The  exchange
olume  may  be  lowered  to  1  if  there  is  clinical  and  lab
mprovement.  Similarly,  it  may  be  increased  in  cases  where
he  patient’s  life  is  at  risk.  At  our  center  plasmapheresis  is
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Suspicion of TTP (thrombocytopenia,
microangiopathic  hemolyt ic anemia,  and  very
high DH L) 
Take blood  samples before sta rting
plasmap heresis . 
Begin plasmapheresis with plasma exchange
at 1.5  vol umes f or the first  3 days,  then  1
volume until the patient stabilizes. Assess
rituximab,  es pecially in  sev ere  cases. 
Response:  >15  x 109/L plat elets ,
normal DH L, clinical improvem ent
for 2 days  in a  row  
Stop plasmapheresis,  eval uate
dail y. 
Refractory: low platelet count,
clinical deterioration. 
Begin ritux imab at 100-3 75 mg/m2 
week ly fo r 4 week s 
Remiss ion : no rmal plat elet counts
30 days after the last
plasmapheresis.
Relapse:  daily plasm apheres is with
plasm a exchange  plus  rituxim ab. 
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continued  until  we  obtain  a  number  higher  than  150  ×  109/L
platelets  and  normal  LDH.  After  reaching  this  number,  the
case  is  monitored  daily  before  deciding  on  a  higher  plasma-
pheresis  sessions.  However,  in  hospitals  or  places  with  higher
economic  resources,  it  is  reasonable  to  continue  with  at
least  2  plasmatic  exchanges  once  TTP  remission  has  been
obtained.
The  use  of  steroids  is  very  controversial.  No  beneﬁts  have
been  clearly  demonstrated,  yet  they  are  widely  used.
Rituximab
When  dealing  with  autoimmune  TTP,  it  is  logical  to  use  an
antibody  whose  targets  are  the  lymphocytes  B  responsible
for  the  immune  response  mediated  by  antibodies.  Such  is
the  case  with  rituximab,  whose  only  objective  is  the  antigen
CD20  on  the  surface  of  the  lymphocytes  B.
The  use  of  rituximab  has  been  suggested  if  there  is
cardiac  or  neurological  compromise.34 However,  its  use  in
all  patients  from  the  start  is  promising.  In  an  acute  TTP
episode,  initial  treatment  with  rituximab,  plasmapheresis
and  corticosteroids  have  an  apparent  remission  in  >90%  of
d
s
s
sement  scheme  of  TTP.
he  patients  within  14  to  21  days  and  may  also  reduce  relapse
requency.34
In  patients  with  an  episode  of  refractory  TTP,  the  addition
f  rituximab  to  plasmapheresis  and  corticosteroids  increases
latelet  counts  in  >80%  of  the  patients  and  may  decrease  the
equired  time  to  accomplish  a  response  platelet  count.35
A  persistent  severe  deﬁciency  of  ADAMTS13  during  remis-
ion  should  lead  to  the  consideration  of  administering
ituximab  as  a  preventive  measure  to  avoid  relapse.36
In  our  center,  we  published  4  cases  of  TTP  treated  with
ow  doses  of  rituximab,  plasmapheresis  and  a  short  steroid
ourse.  Patients  were  administered  100  mg  of  rituximab
ntravenously,  from  the  second  to  eighth  day,  with  the  begin-
ing  of  plasmapheresis  as  a  ﬁrst  line  therapy  in  three  cases
nd  as  a  rescue  therapy  for  relapses  in  one  case.  The  number
f  necessary  plasmaphereses  varied  from  5  to  12  sessions.
ll  patients  reached  complete  remission  and  are  currently
symptomatic,  with  a  duration  of  complete  response  of  8--22
onths.37 We  treated  7  more  patients  for  a  total  of  11  and  in
ata  --  as  yet  unpublished  --  we  accomplished  a  disease-free
urvival  rate  of  2  years  of  90%.  In  Fig.  1  we  present  a  scheme
howing  the  therapeutic  approach  of  TTP  in  different  clinical
cenarios.
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238  
ew treatments
ecombinant  ADAMTS13
 study  was  conducted  in  order  to  ﬁnd  out  whether  or  not  an
DAMTS13  recombinant  is  capable  of  bearing  the  neutraliz-
ng  antibodies  and  restoring  ADAMTS13  activity  in  patients
ith  acquired  TTP.  The  relationship  between  the  amount  of
dded  ADAMTS13  recombinant,  the  recovery  of  ADAMTS13
ctivity  and  the  titles  of  the  anti  ADAMTS13  inhibitors  in  the
atient  was  investigated.
They  demonstrated  that  an  ADAMTS13  recombinant,  at
 reasonable  dose,  has  the  ability  to  bear  the  neutraliz-
ng  inhibitors  and  rebuilding  ADAMTS13  in  vitro  activity  in
cquired  TTP.38
rognosis
efore  plasmapheresis,  TTP  had  a  mortality  rate  of  over  90%,
ut  with  the  use  of  plasmapheresis  mortality  rate  went  down
o  20%.39 Despite  the  major  advances  in  the  reduction  of
he  mortality  rate,  patients  who  survive  TTP  face  a  series
f  challenges:  a  major  morbimortality  rate  compared  to  the
eneral  population,40 as  well  as  a  lower  quality  of  life,  less
ocial  life  and  cognitive  deﬁcits,  in  addition  to  the  risk  of
elapse.41--44 Over  a  third  of  patients  who  survive  an  acute
pisode  of  TTP  will  have  at  least  a  relapse  during  the  fol-
owing  10  years.43 Relapse  rate  is  34%,  most  initial  relapses
mong  patients  with  ADAMTS13  activity  <10%  occur  within
he  ﬁrst  year  after  remission  and  this  rate  decreases  with
ime.44
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